FATE FATE THERAPEUTICS INC
Price Chart
Executive Summary
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highlighting Phase 1 data for FT819 in autoimmune diseases and the upcoming Phase 2 RECLAIM-LN registrational trial in lupus nephritis. The filing also included Q1 2026 financials showing $174.8M cash runway into 2028 and a 20% YoY OpEx reduction, but the primary content is a routine corporate update without new material financial disclosures.
Actionable Insight
This is a routine corporate presentation update with no new material financial data. Key catalyst to watch is the initiation of the RECLAIM-LN Phase 2 trial in 2H 2026 and FT839 IND filing — both binary clinical events. Monitor for patient enrollment updates and potential partnership announcements given the cash runway guidance into 2028.
Key Facts
- Corporate presentation updated for EULAR 2026 Congress on June 4, 2026.
- FT819-102 Phase 1 data: 26 patients dosed (22 SLE, 4 SSc, 3 IIM, 1 AAV); 21 activated clinical sites; 8 patients treated in outpatient settings.
- FT819-102 demonstrated no DLT, no Grade >2 CRS, ICANS, GvHD or deaths in 16 SLE Regimen A patients.
- RECLAIM-LN Phase 2 potentially registrational trial for lupus nephritis planned to begin patient dosing in 2H 2026 with 53-patient enrollment targeting BLA submission in 2028.
- Q1 2026 cash and short-term investments of $174.8M, with cash runway into 2028.
- Total OpEx reduction of 20% YoY in Q1 2026, with R&D down 15% and G&A down 30%.
- Weighted-average shares outstanding of 120.0M.
- FT839 IND filing planned 2H 2026; FT839 Phase 1 pan-autoimmune trial initiation 2H 2026.
Financial Impact
Cash runway into 2028 with $174.8M cash and investments; no revenue or EPS reported in filing.
Risk Factors
- Clinical trial execution risk for RECLAIM-LN Phase 2 enrollment timelines and outcomes.
- Regulatory risk: FT819's registrational path depends on alignment with FDA, which may shift timelines.
- Cash runway into 2028 provides buffer but ongoing R&D spend without revenue creates dilution risk.
- Competition in off-the-shelf CAR T-cell therapy space for autoimmune indications.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257558 |
| Document: d83385d8k.htm | 0001193125-26-257558 |
| Document: 0001193125-26-257558-index-headers.html | 0001193125-26-257558 |
| Document: 0001193125-26-257558-index.html | 0001193125-26-257558 |
| Document: 0001193125-26-257558.txt | 0001193125-26-257558 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $1.95 awaiting T+5 | awaiting T+5 | — | $2.06 (−5.64%) |
|
Jun 4, 2026
8d ago
|
8-K
| $2.15 awaiting T+5 | awaiting T+5 | — | $2.06 (−4.19%) |
|
Jun 1, 2026
11d ago
|
Press Release
| $2.74 $1.98 | ▼ −27.74% | ▼ −24.99% | $2.06 (−24.82%) |
|
May 13, 2026
4w ago
|
8-K
| $2.14 $1.89 | ▼ −11.68% | ▼ −10.52% | $2.06 (−3.74%) |
|
May 11, 2026
4w ago
|
Press Release
| $2.18 $1.73 | ▼ −20.64% | ▼ −20.56% | $2.06 (−5.50%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $1.31 $1.80 | ▲ +37.40% | ▲ +37.00% | $2.06 (+57.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access